SITE006 (GBR) › SITE006-0048

SITE006-0048

A Phase III, Randomized, Double-Blind Study of Torivumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Previously Untreated Advanced Non-Small Cell Lung Cancer · Phase III
SITE006 (GBR) · Dr. Rossi
consented 2025-10-30

withdrawn

AEs

Serious

Dropout signal

–

Adverse events

Grade 2 Asthenia — outcome: RECOVERED/RESOLVED; onset 2022-06-01 (study day 28); relationship: not assessed

moderate assessed

Grade 1 Fatigue — outcome: RECOVERED/RESOLVED; onset 2022-05-19 (study day 15); relationship: RELATED

mild assessed

Grade 3 Decreased appetite — outcome: RECOVERED/RESOLVED; onset 2022-05-18 (study day 14); relationship: not assessed; serious criteria: hospitalization

severe serious assessed

Grade 1 Peripheral neuropathy — outcome: RECOVERED/RESOLVED; onset 2022-05-16 (study day 12); relationship: NOT RELATED

mild assessed

Data queries

No data queries. Open queries would appear here for this patient.